Kazia Therapeutics Limited Overview
Kazia Therapeutics is a Sydney-headquartered, Nasdaq-listed, clinical-stage oncology company. It in-licenses scientifically differentiated assets and develops them through partnered and investigator-led trials. Its value is concentrated in paxalisib, a brain-penetrant PI3K/Akt/mTOR inhibitor licensed from Genentech in 2016. Paxalisib carries FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations across glioblastoma, brain metastases, DIPG and AT/RT.
After paxalisib's GBM AGILE Phase 2/3 result in 2024 fell short of a clear registrational path, management repositioned the asset toward metastatic breast cancer. Early Phase 1b triple-negative breast cancer (TNBC) data in combination with pembrolizumab and chemotherapy showed an 83% objective response rate in six evaluable patients (August 2026), and an HR+/HER2- expansion followed.
Around paxalisib, Kazia has assembled an early immuno-oncology/epigenetics layer: NDL2 (an intracellular PD-L1 degrader) and MSETC (a SETDB1 inhibitor), both licensed from QIMR Berghofer. EVT801 (a VEGFR3 inhibitor from Evotec) remains a secondary clinical asset. Balance-sheet repair in 2025–26 transformed a going-concern situation into a funded, catalyst-rich micro-cap.
Company's own description
In its FY2025 Form 20-F, Kazia describes itself as an emerging, oncology-focused biotechnology company developing brain-penetrant and tumour-targeted small-molecule therapeutics. It names paxalisib and EVT801 as its principal product candidates. The FY2024 Directors' Report frames its principal activity as pharmaceutical research and development, with commercialisation of research results intended through license transactions "or other means."
From mid-2026, corporate boilerplate was updated. Kazia now describes itself as an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumour immunity and overcome treatment resistance (press releases, 27–31 August 2026). This signals a strategic rebranding from a "brain cancer company" to a "resistance-biology platform company."
Independent characterisation
Kazia is best characterised as a virtual, asset-centric drug developer:
Asset sourcing: It does not run discovery chemistry at scale. It acquires rights from large pharma (Genentech: paxalisib), European biotech (Evotec: EVT801) and Australian academic institutes (QIMR Berghofer: NDL2, MSETC).
Clinical execution: It relies heavily on cooperative groups, academic sponsors and platform trials, including GBM AGILE, Memorial Sloan Kettering, Dana-Farber, PNOC, the University of Sydney/COGNO (LUMOS2) and ANZCHOG (OPTIMISE). This capital-light model explains how a company with fewer than 15 staff has supported more than 15 paxalisib trials.
Monetisation: Kazia monetises regional rights through out-licensing. Examples are Simcere for Greater China (2021) and Sovargen for a rare-epilepsy indication (FY2024). Earlier, Oasmia licensed Cantrixil.
Revenue model
| Revenue type | Status | Evidence |
|---|---|---|
| Product sales | None. The company has never generated product revenue | 20-F risk factors (FY2023, FY2025) |
| Licensing (upfront / milestones / royalties) | Sole historical revenue source; irregular | FY2021 A$15.18M (Simcere + Oasmia); FY2024 A$2.31M; FY2025 A$0.042M |
| Services / subscription | — | — |
| Other income | R&D tax incentive rebates; sundry income; fair-value gains on liabilities | FY2025 R&D rebate A$209k, sundry income A$1.6M (20-F FY2025) |
Value-chain position, customers and end-markets
Value-chain position: Upstream clinical development, from Phase 1 to Phase 2/3. Kazia has no manufacturing, sales force or distribution infrastructure.
"Customers" today: Licensees such as Simcere (China), Sovargen (South Korea) and Oasmia (Sweden). Prospectively, they are pharma partners for regional or global rights.
Ultimate end-markets (if approved): - Neuro-oncology: glioblastoma, brain metastases, DIPG/DMG, AT/RT, PCNSL
-
Metastatic breast cancer: TNBC, HR+/HER2-
-
Checkpoint-inhibitor-resistant solid tumours: NSCLC and breast (NDL2, MSETC)
-
Advanced solid tumours, including ovarian (EVT801)
Strategy
Stated strategy (themes from filings, AGM materials and 2026 releases)
-
Reposition paxalisib beyond neuro-oncology. The H1 FY2026 report notes the company advanced paxalisib beyond neuro-oncology during the period. Breast cancer (TNBC, then HR+/HER2-) is now the primary value-driver, with enrichment via a proprietary epigenetic PI3K/mTOR biomarker (liquid and tissue tests).
-
Preserve the GBM optionality. Kazia is pursuing discussions on a pivotal registrational GBM study for standard approval, following GBM AGILE.
-
Build a "multi-layered" resistance-biology platform. Three layers: chromatin regulation (SETDB1/MSETC), immune checkpoint degradation (NDL2) and oncogenic signalling (paxalisib). Management describes this as addressing cancer across multiple layers of tumour biology (April 2026).
-
Precision medicine and AI-guided discovery through the QIMR platform and the CSO's liquid/spatial epigenetic biomarker capabilities.
-
Early partnering of preclinical assets (MSETC flagged for early strategic partnering).
-
US capital-markets focus. ASX delisting, US-based CFO, and bulge/specialist bookrunners (Leerink, Guggenheim).
Initiative register (last 24 months)
| Date | Initiative | Category | Targets / metrics |
|---|---|---|---|
| Jan 2025 | Advanced breast cancer trial (paxalisib + immunotherapy) approved and launched | Clinical expansion | — |
| Apr 2025 | ADS ratio change (1:500) | Listing maintenance | Nasdaq US$1 minimum bid |
| Jun 2025 | Phase 1b TNBC first patient | Clinical | 12 TNBC patients by end-2026 (Jan 2026 guidance); now enrolment complete July 2027 and expansion to 36 |
| Oct 2025 | NDL2 in-license | Platform / immuno-oncology | Clinic by early 2027 |
| Dec 2025 | US$50M PIPE | Financing | Eliminated going-concern overhang |
| Apr 2026 | SETDB1/MSETC platform in-license | Platform / epigenetics | IND-enabling studies |
| Apr–Jun 2026 | CSO and CFO appointments | Leadership | — |
| Aug 2026 | Milestone-linked warrant financing | Financing | Series A tied to Stage IV TNBC readout (2H 2027); Series B tied to HR+/HER2- readout (1H 2028) |
| ~Oct 2026 | HR+/HER2- three-arm expansion + provisional patent | Clinical / IP | Readout 1H 2028 |
Medium-term financial targets. None. Kazia provides no revenue, EBITDA or profitability guidance. Its only quantitative guidance consists of clinical timelines.
ESG / sustainability commitments. No quantitative commitments disclosed.
Products & Services
Kazia has no marketed products. The catalogue below is the full development pipeline, organised by asset.
Paxalisib (formerly GDC-0084) — lead asset
| Attribute | Detail |
|---|---|
| Mechanism | Oral, once-daily, brain-penetrant small-molecule inhibitor of the PI3K/Akt/mTOR pathway (dual PI3K/mTOR) |
| Origin | Licensed from Genentech (Roche group), late 2016 |
| Clinical footprint | Subject of more than 15 clinical trials (company boilerplate, Aug 2026) |
| Regulatory designations (FDA) | Orphan Drug — GBM (Feb 2018); Fast Track — GBM (Aug 2020); Rare Pediatric Disease + Orphan Drug — DIPG (Aug 2020); Rare Pediatric Disease — AT/RT (Jun 2022); Orphan Drug — AT/RT (Jul 2022); Fast Track — PI3K-mutated solid-tumour brain metastases with radiotherapy (Jul 2023) |
| Regional licensees | Simcere (Greater China: Mainland China, Hong Kong, Macau, Taiwan) — responsible for development, registration and commercialisation, with mid-teen royalties (AR 2022). Sovargen (South Korea) — rare epilepsy indication (FY2024) |
| IP | Loss of exclusivity "no earlier than 2030 in any territory" (half-year report Dec 2022). New provisional patent (2026) on an epigenetic PI3K/mTOR biomarker in HR+ breast cancer |
| Pricing | Not applicable (pre-commercial) |
| Indication | Trial / sponsor | Phase | Status (latest disclosed) |
|---|---|---|---|
| Glioblastoma (newly diagnosed, MGMT-unmethylated) | GBM AGILE (Global Coalition for Adaptive Research) | Phase 2/3 | Completed; reported 2024. Kazia is in discussion on designing and executing a pivotal registrational study for standard approval (Aug 2026 boilerplate) |
| Stage IV metastatic TNBC | Kazia-sponsored, multi-centre, open-label, randomised Phase 1b (ACTRN12624001340527); paxalisib 30 mg daily + pembrolizumab + chemotherapy | Phase 1b | Initiated June 2025. Six evaluable patients: 1 CR, 4 PR, 1 SD (ORR 83%, CBR 100%). No paxalisib-related SAEs; no Grade ≥3 hyperglycaemia/stomatitis/mucositis (27 Aug 2026). Enrolment completion expected July 2027. Expansion planned from 12 to 36 patients (2026 6-K) |
| BRCA-mutated advanced breast cancer | Same Phase 1b study — paxalisib + olaparib arm | Phase 1b | Ongoing; no efficacy data disclosed in sources reviewed |
| HR+/HER2- metastatic breast cancer (pre-treated, incl. CDK4/6-inhibitor-resistant) | Three-arm expansion of the TNBC protocol | Phase 1b expansion | Announced ~1 Oct 2026, supported by preclinical resensitisation data. Readout expected 1H 2028 (per Series B warrant terms) |
| Brain metastases (with radiotherapy) | Memorial Sloan Kettering Cancer Center (with two additional centres) | Phase 1 (expansion cohort) | Expansion cohort enrolling from 2023; ongoing |
| Diffuse midline glioma / DIPG | Pacific Pediatric Neuro-Oncology Consortium (PNOC022) and related studies | Phase 2 | Ongoing (boilerplate) |
| Primary CNS lymphoma | Investigator-led (Dana-Farber, per historic disclosures) | Phase 2 | Ongoing (boilerplate) |
| IDH-mutant grade 2/3 glioma | LUMOS2 — University of Sydney / NHMRC CTC / COGNO | Phase 2 | Supported since June 2023 |
| Paediatric advanced solid tumours incl. brain tumours | OPTIMISE — ANZCHOG | Phase 2 | Collaboration announced FY2023 |
| AT/RT | Investigator studies / designations | Early | RPDD + ODD granted 2022 |
| Rare epilepsy | Sovargen (licensee) | Partner-led | Licensed FY2024 |
EVT801
| Attribute | Detail |
|---|---|
| Mechanism | Selective small-molecule inhibitor of VEGFR3 (anti-lymphangiogenic; tumour-microenvironment modulation) |
| Origin | Licensed from Evotec SE, April 2021 |
| Development stage | Phase 1 in advanced solid tumours completed (FY2024 Annual Report), with encouraging results particularly in ovarian cancer |
| Milestone exposure | Unbooked contingent milestones of €300.5M (A$456M) at 30 June 2022 (AR 2022, Note 16) |
| Current priority | Secondary; potential combination partner for NDL2 and paxalisib |
NDL2 — intracellular PD-L1 protein degrader
| Attribute | Detail |
|---|---|
| Modality | Bicyclic peptide degrader recognising post-translationally modified PD-L1 and recruiting cellular disposal machinery. Degrades PD-L1 across surface, cytoplasmic and nuclear compartments |
| Origin | Exclusive collaboration and in-licensing agreement with QIMR Berghofer, 7 Oct 2025. Inventor: Prof. Sudha Rao (now Kazia CSO) |
| Deal terms | ~US$1.39M one-time payment; Kazia bears all development costs; shares a percentage of commercialisation revenue, including out-licensing receipts (TheFly / company release) |
| Preclinical evidence | Tumour growth reduction in aggressive TNBC models, as monotherapy and with anti-PD-1 |
| Initial indications | Advanced breast cancer; non-small cell lung cancer |
| Timeline | Clinical entry targeted by early 2027 (ApexOnco/OncologyPipeline report) |
| Competitive note | Described by QIMR Berghofer as the most advanced PD-L1 degrader in development globally |
MSETC — SETDB1 inhibitor and AI-integrated epigenetic platform
| Attribute | Detail |
|---|---|
| Modality | Highly selective bicyclic peptide targeting a disease-associated nuclear SETDB1 complex (not the isolated enzyme) |
| Platform | AI-integrated epigenetic drug-discovery engine developed at QIMR Berghofer; capable of generating follow-on candidates |
| Deal | License and Commercialisation Agreement signed 10 Apr 2026 (announced 13 Apr 2026). Exclusive, worldwide rights. ~US$1.39–1.4M upfront plus tiered revenue sharing aligned with development progress (BioWorld, Fierce Biotech) |
| Rationale | Restore immune signalling in tumours resistant to checkpoint inhibitors |
| Stage | Preclinical; next milestone is IND-enabling studies, run in parallel with NDL2 |
| Strategy | Framed as a candidate for early strategic partnering |
Divested / legacy assets
| Asset | Status |
|---|---|
| Cantrixil (TRX-E-002-1; ovarian cancer) | Out-licensed to Oasmia Pharmaceutical AB (Sweden) in FY2021: US$4M upfront, up to US$42M milestones, double-digit royalties. |
| Legacy Novogen consumer/isoflavone businesses | Divested in earlier eras (pre-2016); details outside the 10-year window |
Financial Narrative
Basis: IFRS consolidated statements; A$ millions unless stated. Sources: Annual Report / Appendix 4E FY2022 (FY2021–22 as originally reported), Form 20-F FY2024 (FY2022 restated, FY2023, FY2024), Form 20-F FY2025 (FY2023–25 net losses and FY2025 data), Half-Year Report 31 Dec 2025 (H1 FY2026).
Income statement
H1 FY2026 (six months to 31 Dec 2025), A$: loss after tax A$12.55M (H1 FY2025: A$10.45M); operating cash outflow A$9.54M (H1 FY2025: A$8.42M); other comprehensive loss A$0.86M.
Commentary. Kazia's P&L is a function of trial spending and deal timing. The FY2021 profile was flattered by US$11M of upfront licensing receipts (Simcere US$7M implied, Oasmia US$4M). In FY2022–FY2024, net losses of A$20–27M reflect peak spending on GBM AGILE, paediatric programmes and EVT801's Phase 1. The FY2025 R&D collapse to A$7.3M (from A$17.4M) was not strategic retrenchment by choice. It was forced by a liquidity crisis: cash fell to A$1.66M at June 2024 and the going-concern opinion followed in FY2025.
The H1 FY2026 loss of A$12.55M (versus A$10.45M) marks a re-acceleration of spending once the December 2025 PIPE closed. Expect FY2026 and FY2027 losses to rise materially as TNBC/HR+ trials expand and NDL2/MSETC move through IND-enabling work.
Balance sheet
Sources: AR 2022 Notes 9, 17, 18; 20-F FY2024 XBRL (cash series, GBM AGILE deposit); 20-F FY2023 (accumulated losses A$89.1M); edgar.tools/20-F FY2025 (total assets, liabilities); Half-Year Report Dec 2025 (net current liability at 30 June 2025). FY2025 equity is derived arithmetically: 6.06 − 14.36.
Position at 31 December 2025 (H1 FY2026):
-
Cash: A$69.46M
-
Net current assets: A$45.61M
-
Net assets: A$46.47M (turned positive from a deficit)
Debt. Kazia carries no conventional bank debt. Liabilities consist of trade payables, contingent consideration (EVT801 milestones assessed as probable), "other financial liabilities", a promissory note (FY2024 remeasurement gain A$25k) and a deferred tax liability. A short/long-term debt split, net debt and net debt/EBITDA are therefore not applicable. Net cash equals cash.
Goodwill and intangibles. Licensed assets (paxalisib, EVT801) are carried as separately acquired intangibles at cost and amortised (AR 2022, Note 2). Current carrying values were not captured in sources reviewed.
Cash flow
Change in cash is derived from year-end cash balances. FY2025 equity raised is per the 20-F FY2025 summary. Operating cash flow by full year was not captured; H1 FY2026 operating outflow was A$9.54M and H1 FY2025 was A$8.42M. Capex is immaterial for a virtual company and none was separately disclosed in sources reviewed. Free cash flow approximates operating cash flow.
Ratios
These are analyst-derived from the tables above. Runway = cash ÷ |net loss| and is a crude proxy, since net loss includes non-cash items.
Ratios not meaningful or not applicable:
-
ROE, ROA and ROIC: negative or NM, with equity negative at FY2025.
-
Current ratio: below 1.0x at FY2025 (net current liability A$9.12M). Sharply above 1.0x at December 2025.
-
Debt/equity, net debt/EBITDA, interest coverage: no funded debt.
-
Asset turnover: NM.
-
Cash conversion cycle: no inventory or receivables cycle.
Trend synthesis. Three phases are visible:
-
FY2021 (licensing peak): cash A$27.6M, lowest loss.
-
FY2022–FY2024 (investment phase): losses of A$20–27M per year, cash depleted to A$1.66M. Survival depended on remeasurement gains, deposits held by GBM AGILE and dribbling equity issues at heavily discounted prices.
-
FY2025–H1 FY2026 (crisis and recapitalisation): going-concern doubt and a forced R&D cut, then the December 2025 PIPE and the August 2026 offering. Pro forma, Kazia likely holds well above US$80M in cash (A$69.5M at December 2025, less H2 FY2026 burn, plus ATM proceeds and ~US$37M net from August 2026). The exact current balance is not publicly disclosed as of this report.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Jurisdiction | Function (analyst interpretation) |
|---|---|---|
Kazia Therapeutics Limited | NSW, Australia | Listed parent; holds licenses; R&D sponsor |
Kazia Research Pty Ltd | Australia | Research subsidiary (likely R&D tax incentive vehicle) |
Kazia Therapeutics Inc. | United States | US operations / clinical and investor presence |
Glioblast Pty Ltd | Australia | Subsidiary (legacy/asset-holding; purpose not detailed in sources reviewed) |
Revenue by Segment
| Segment | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Pharmaceutical R&D — licensing revenue (AUD Mn) | 15.18 | 0 | 0 | 2.31 | 0.042 |
% contribution to total revenue | 100 | 0 | 0 | 100 | 100 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Loss after income tax (AUD Mn) | -8.42 | -25.01 | -20.47 | -26.78 | -20.70 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue — licensing (AUD Mn) | 15.18 | 0 | 0 | 2.31 | 0.042 |
Other income (AUD Mn) | — | 0.025 | 0.001 | 0.173 | — |
Finance income (AUD Mn) | — | 0.002 | 0.022 | 0.012 | 0.072 |
R&D expenditure, company-sponsored (AUD Mn) | — | — | 15.6 | 17.4 | 7.3 |
Gain on remeasurement of contingent consideration (AUD Mn) | — | — | 3.388 | 0.119 | — |
Loss before income tax (AUD Mn) | -8.91 | -25.38 | -20.74 | -27.05 | — |
Income tax benefit (AUD Mn) | 0.48 | 0.37 | 0.27 | 0.27 | — |
Net loss after tax (AUD Mn) | -8.42 | -25.01 | -20.47 | -26.78 | -20.70 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD Mn) | 27.59 | 7.36 | 5.24 | 1.66 | 4.30 |
GBM AGILE deposit receivable (AUD Mn) | — | — | 3.75 | 3.76 | — |
Total assets (AUD Mn) | — | — | — | — | 6.06 |
Total liabilities (AUD Mn) | — | — | — | — | 14.36 |
Shareholders' equity (AUD Mn) | — | — | — | — | -8.30 |
Net current assets (AUD Mn) | — | — | — | — | -9.12 |
Deferred tax liability — licensing (AUD Mn) | 2.93 | 2.56 | — | — | — |
Contributed equity (AUD Mn) | 80.29 | 84.48 | — | — | — |
Accumulated losses (AUD Mn) | — | — | 89.1 | — | — |
Balance Sheet — Change in cash
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Change in cash (AUD Mn) | — | -20.23 | -2.12 | -3.58 | 2.64 |
Equity raised from ADS sales (AUD Mn) | — | — | — | — | 16.0 |
Capital expenditure (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Instrument by Date
| Date | Instrument | Gross | Net / notes |
|---|---|---|---|
Oct 2020 | ANREO placement + retail at A$0.80 | A$16.4M institutional + retail | AR 2022 |
FY2023 | Placement + Share Purchase Plan | A$7.106M | AR 2023 |
Feb–May 2025 | F-1 registered offering (No. 333-284606) | Not captured | Prospectus 5 Feb 2025 |
FY2025 total | ADS sales | A$16.0M | 20-F FY2025 |
2 Dec 2025 | PIPE (private placement) | ~US$50.0M | ~US$46.5M net (Half-Year Report). BioWorld reported "AU$50M (US$33.15M)" — conflicting with the company's US$ figures; the company figure is preferred |
H2 FY2026 | New at-the-market (ATM) program | — | StockTitan summary of 6-K, Mar 2026 |
28–31 Aug 2026 | Tranched registered offering (F-3 No. 333-294392): 2.58M ADSs or pre-funded warrants + Series A and Series B warrants | US$40M upfront | Up to US$80M additional if warrants are fully exercised |
“—” = not publicly disclosed.
Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net loss / average cash (x) | — | 1.44 | 3.29 | 7.79 | 7.03 |
Cash runway at year-end FY loss rate (years) | 3.28 | 0.29 | 0.26 | 0.06 | 0.21 |
Revenue by Region
| Region (licensee country) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
China — Simcere (AUD Mn) | 10.01 | 0 | 0 | 0 | 0 |
Sweden — Oasmia (AUD Mn) | 5.18 | 0 | 0 | 0 | 0 |
South Korea — Sovargen (AUD Mn) | 0 | 0 | 0 | 2.31 | 0 |
Unallocated / not disclosed (AUD Mn) | 0 | 0 | 0 | 0 | 0.042 |
Total (AUD Mn) | 15.18 | 0 | 0 | 2.31 | 0.042 |
Capital Markets
| Measure | Value | Source / date |
|---|---|---|
Recent price | 10.56 (intraday) | Yahoo Finance, ~21 Sep 2026 |
52-week range | 4.86 – 17.40 | Yahoo / Google Finance |
YTD 2026 total return | +63.39% | Yahoo, as of 21 Sep 2026 |
1-year total return | +36.02% | Yahoo, as of 21 Sep 2026 |
3-year and 5-year return | Deeply negative (market cap fell to ~US$4–10M in September–October 2025; two reverse ADS ratio actions). | TipRanks history |
Offering price reference | 15.50 combined (28 Aug 2026) | Pricing release |
Market Valuation
| Metric | 2025-09 | 2025-10 | 2026-03 | 2026-04 | 2026-07 | 2026-09 |
|---|---|---|---|---|---|---|
Market cap (USD Mn) | 4.2 | 9.7 | 81.5 | 109.1 | 151.9 | 120.6 |
Valuation Multiples
| Multiple | Kazia | Comment |
|---|---|---|
EV (illustrative) | Market cap less cash (likely US$80M+ pro forma) suggests a low EV, possibly US$50–70M. Not computed precisely because current cash is undisclosed | Analyst judgement |
Analyst Ratings & Targets
| Broker | Analyst | Rating | Price target (USD) | Date |
|---|---|---|---|---|
BTIG | Kambiz Yazdi | Buy | 34 | 15 Jul 2026 |
Lake Street | Chad Messer | Buy (initiation) | 32 | 11 Jun 2026 |
Maxim Group | Naz Rahman | Buy | 30 | 15 Jul 2026 |
H.C. Wainwright | Sean Lee | Buy | 18 | 2026 |
Consensus | — | Strong Buy / Buy (4–6 analysts) | 28.50 – 28.87 average | Google Finance; Yahoo (Sep 2026) |
Capital Markets — Dividend history / policy
| Item | Status |
|---|---|
Dividend history / policy | None paid in FY2021–FY2025; no dividend policy (Appendix 4E FY2022; 20-F) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | No funded debt |
Outstanding derivative equity | Series A warrants: up to 2,243,478 ADSs at US$17.825. Series B warrants: up to 2,064,000 ADSs at US$19.375. Pre-funded warrants (number not disclosed). Prior-round warrants likely outstanding from the PIPE (terms not captured) |
Analyst Conclusions
Management guidance (clinical, not financial)
| Item | Guidance | Source |
|---|---|---|
| TNBC Phase 1b enrolment | Completion by July 2027, with interim updates throughout 2026–27 (earlier guidance: 12 patients by end-2026, topline early 2027) | 27 Aug 2026 release; 27 Jan 2026 release |
| Stage IV TNBC data readout | Expected 2H 2027 (Series A warrant trigger) | 28 Aug 2026 pricing release |
| HR+/HER2- data readout | Expected 1H 2028 (Series B warrant trigger) | Same |
| NDL2 clinical entry | Early 2027 | ApexOnco report on company statements |
| MSETC | IND-enabling studies; early partnering | 13 Apr 2026 release |
| GBM | Design of pivotal registrational study under discussion | Corporate boilerplate |
| Financial guidance | None issued | — |
Consensus growth expectations. Revenue consensus is not meaningful. Sell-side targets (US$18–34) imply 70–220% upside from ~US$10.56, reflecting probability-weighted breast cancer value.
Bull case
-
Breast cancer data scale: if ORR remains above 50% and the tolerability edge persists as the TNBC cohort grows from 6 to 36, paxalisib becomes a credible add-on to the pembrolizumab + chemotherapy backbone. It would also gain strategic relevance to Merck-centric combination strategies.
-
HR+/HER2- resensitisation validated: a biomarker-enriched population in a segment of 60–70% of breast cancers, with an oral, brain-penetrant agent, could support a pharma partnership worth multiples of today's ~US$120–150M market cap. Warrant exercise would add up to US$80M.
-
Platform optionality is cheap: two first-in-class preclinical assets cost under US$3M upfront combined. Any NDL2 IND clearance or MSETC partnering would be accretive against a low enterprise value.
Bear case
-
Small-n mirage: six patients, single-arm, with expanded-access anecdotes. PI3K/mTOR toxicity and response durability may disappoint at scale, as many PI3K programmes have historically.
-
Crowded field and partner scepticism: three approved PI3K/AKT agents plus gedatolisib in Phase 3 mean Kazia must show clear differentiation to command a deal. GBM remains unpartnered after GBM AGILE.
-
Execution and governance fragility: a ~6-person company with a three-member board, recurring dilution (two ADS ratio changes in six months, ATM in place) and readouts in 2H 2027 / 1H 2028 faces long cash-burn periods. Warrant capital is contingent and may never arrive.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Q4 2026 | Interim TNBC updates (n>6); HR+ arm activation; possible conference presentations (subject to IP strategy) |
| Q4 2026 – Q1 2027 | Appointment of a permanent Chair and board expansion |
| Nov 2026 (est.) | FY2026 Form 20-F: full-year loss, cash, going-concern language (expected to be removed) |
| Early 2027 | NDL2 IND/CTN filing and first-in-human start |
| H1 2027 | Half-year report; burn rate post-expansion |
| 2,027 | GBM registrational study decision and FDA alignment; any partnering (MSETC, regional paxalisib rights) |
| Ongoing | ATM usage and dilution; warrant overhang dynamics versus US$17.825 / US$19.375 strikes; Nasdaq compliance |
Concluding analyst verdict
Kazia Therapeutics has executed one of the more striking micro-cap turnarounds in Nasdaq-listed Australian biotech. In under twelve months it went from a going-concern warning with A$4.3M cash and a market value near US$4M (September 2025) to a recapitalised company. It held A$69.5M in cash at December 2025, raised a further ~US$40M upfront in August 2026, and enjoys broad Buy-rated sell-side coverage.
The turnaround rests on a strategic pivot. Paxalisib, a once neuro-oncology-only asset whose GBM AGILE outcome failed to deliver a direct approval route, has been redeployed into metastatic breast cancer. There, early data are eye-catching: an 83% ORR and 100% CBR in six Stage IV TNBC patients without the hallmark PI3K toxicities. Around it, management has bolted on two inexpensive, first-in-class preclinical platforms from QIMR Berghofer and brought their inventor in as CSO.
The investment case, however, remains a binary, data-dependent proposition with a long fuse. The decisive readouts (TNBC in 2H 2027, HR+/HER2- in 1H 2028) are 12–20 months away, and the financing structure explicitly ties incremental capital to them. Six patients is not a dataset. The PI3K-pathway breast cancer market is crowded with large-pharma incumbents, and the company's operational and governance bench is extremely thin for the ambitions now articulated.
Verdict: Speculative positive / high risk. The asymmetry is genuine: a low enterprise value relative to cash, warrant-aligned financing and multiple shots on goal. But expected value hinges on replication of the TNBC signal at n=36 and on credible HR+ differentiation.
Key watch items: interim breast cancer updates, board reinforcement, FY2026 20-F cash disclosure, and NDL2's entry into the clinic. Failure on any of the first two would likely re-rate the equity sharply lower given the dilution history.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / education | Source |
|---|---|---|---|---|
Dr John Friend, B.A., M.D. | Chief Executive Officer; Managing Director | CEO since 1 May 2023 (previously Chief Medical Officer); MD since 1 Aug 2023; Interim Chair 11 Aug 2023 – 18 Jan 2024 | US-trained physician; practised medicine in North Carolina. Roughly 15 years in oncology/haematology drug development across start-ups and multinationals | Annual Report 2023; FY2024 Directors' Report |
James Levine | Chief Financial Officer | Since 1 Jun 2026 | CFO, Cardiff Oncology. CFO, Cidara Therapeutics (structured the US$568M Mundipharma licensing and US$780M Janssen partnership). CEO, Verenium (~US$200M asset sales). CEO, Sapphire Energy. 12 years at Goldman Sachs as Managing Director in healthcare | Press release, 2 Jun 2026 |
Prof. Sudha Rao | Chief Scientific Officer | Since 15 Apr 2026 | Leads the Gene Regulation and Translational Medicine Laboratory at QIMR Berghofer. Former senior scientist at Sanofi/Rhône-Poulenc (UK). Lead inventor on 39 international patents. Inventor of NDL2 and MSETC | Press release, 15 Apr 2026 |
Karen Krumeich | Former CFO | Appointed c.2023–24; succeeded by Levine (June 2026) | Departure date and context not disclosed in sources reviewed | Quantisnow headline archive |
Anna Sandham | Company Secretary | — | BEc, Grad.Dip.AppCorpGov, FGIA | Annual Report 2023 |
Board of Directors
| Name | Role | Tenure | Background |
|---|---|---|---|
Dr John Friend | Managing Director & CEO (executive) | Board since Aug 2023 | As above |
Steven Coffey | Non-Executive Director | Pre-2023; re-elected at AGM 25 Mar 2026 (1,050,412,780 votes for) | Background details not captured in sources reviewed |
Ebru Davidson | Non-Executive Director; member, Audit, Risk & Governance Committee (from 31 Mar 2026) | Since 5 Jun 2023 | Corporate lawyer; General Counsel, QBiotics Group |
Bryce Carmine | Former Chairman | Director 2015 – 31 Mar 2026; Chair 18 Jan 2024 – 31 Mar 2026 | Ex-Eli Lilly: President, Global Pharmaceutical Product Development; EVP/President Established Markets 2010–12; President, Lilly Japan 1995–99 |
Robert Apple | Former Non-Executive Director | Appointed 15 Jan 2024; departure date not captured | Former Antares Pharma board member (2016–May 2022); prior boards include InKine, PaxMedica, Kerathin |
Iain Ross | Former Chairman | Chair c.2015 – 11 Aug 2023 | — |
Dr James Garner | Former CEO & MD | c.2016 – May 2023 | Led Novogen-to-Kazia transformation; in-licensed paxalisib and EVT801 |
Major Shareholders
| Holder category | Detail |
|---|---|
Top 10 institutional holders | Not publicly disclosed in sources reviewed. 13G filings exist historically; the December 2025 PIPE and August 2026 offering (Leerink/Guggenheim-led) likely introduced specialist healthcare funds. |
Insider ownership | Low. Example: Bryce Carmine held 856,681 ordinary shares (~0.01%) as of September 2025 (MarketScreener) |
ADS vs ordinary | Following the ASX delisting, nearly all trading occurs via ADSs (1:500) |
Competitive Landscape
Competitors by Segment
| Programme | Competitor | Asset / approach | Positioning vs Kazia |
|---|---|---|---|
GBM | Novocure | Optune (tumour treating fields), marketed | Established standard adjunct; Kazia would be additive |
GBM / glioma | Servier | Vorasidenib (IDH1/2 inhibitor; approved 2024 for IDH-mutant glioma) | Different molecular segment (IDH-mutant vs unmethylated GBM) |
DMG/DIPG | Jazz Pharmaceuticals (acquired Chimerix, 2025) | Dordaviprone (ONC201) | Approved for H3 K27M DMG (2025); raises bar in DIPG |
Paediatric glioma | Day One Biopharmaceuticals | Tovorafenib (Ojemda), marketed | BRAF-altered pLGG; adjacent |
GBM | CNS Pharmaceuticals, Plus Therapeutics, Telix | Berubicin; radiotherapeutics; TLX101 | Micro/small-cap peers in recurrent GBM |
PI3K pathway, breast | Novartis | Alpelisib (Piqray) | PIK3CA-mutant HR+; hyperglycaemia limits use. Kazia claims cleaner tolerability |
PI3K/AKT, breast | AstraZeneca | Capivasertib (Truqap) | Approved HR+/HER2- with PIK3CA/AKT1/PTEN alterations |
PI3Kα, breast | Roche | Inavolisib (Itovebi) | Approved first-line PIK3CA-mutant HR+ |
PI3K/mTOR, breast | Celcuity | Gedatolisib (IV pan-PI3K/mTOR) | Closest mechanistic analogue in HR+/HER2-; ahead in Phase 3 |
Mutant-selective PI3Kα | Relay Therapeutics; Eli Lilly (via Scorpion asset acquisition) | RLY-2608; STX-478 | Next-generation, mutant-selective, lower hyperglycaemia |
TNBC immunotherapy | Merck; Gilead; AstraZeneca/Daiichi Sankyo | Pembrolizumab (backbone); sacituzumab govitecan (Trodelvy); datopotamab deruxtecan | Kazia positions as add-on to the pembro + chemo backbone |
PD-(L)1 next-gen | Summit/Akeso; BioNTech; others | PD-(L)1 x VEGF bispecifics | Alternative route to checkpoint resistance; NDL2 is the only clinical-track degrader per QIMR |
VEGFR3 / lymphangiogenesis | Various (no direct clinical-stage selective VEGFR3 peer identified) | — | EVT801 differentiated but low priority |
Peer Comparison FY2025
| Company | Latest FY revenue (USD Mn) | Growth | Profitability | R&D intensity | Stage |
|---|---|---|---|---|---|
Kazia Therapeutics (FY2025, A$) | 0.03 (A$0.042M) | −98% | Net loss A$20.7M | R&D A$7.3M; NM % | Phase 1b–3 |
Novocure (FY2024) | — | — | Loss-making | High | Commercial |
Celcuity (FY2024) | 0 (pre-revenue) | — | Loss-making | — | Phase 3 |
Day One Biopharmaceuticals (FY2024) | — | Launch year | Loss-making | High | Commercial |
Recent Developments
--



